Press releaseGlobe Newswire
Fortress Biotech
FBIOP · NASDAQ
$16.45−$0.22 (−1.32%)TodayMarket closed ·
Prev close $16.67
Latest news
- Press releaseGlobe Newswire
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
- Press releaseGlobe Newswire
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
- Press releaseGlobe Newswire
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
- Press releaseGlobe Newswire
Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- Press releaseGlobe Newswire
UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
- Press releaseGlobe Newswire
Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
- Press releaseGlobe Newswire
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
- Press releaseGlobe Newswire
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission
- Press releaseGlobe Newswire
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
- Press releaseGlobe Newswire
Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
- Press releaseGlobe Newswire
Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights
- Press releaseGlobe Newswire
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
- Press releaseGlobe Newswire
Fortress Biotech to Participate in October 2024 Investor Conferences
- Press releaseGlobe Newswire
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.